Page 445 - Williams Hematology ( PDFDrive )

420 Part V: Therapeutic Principles

202. Hamid O, Robert C, Daud A, et al: Safety and tumor responses with lambrolizumab 207. Budde LE, Berger C, Lin Y, et al: Combining a CD20 chimeric antigen receptor and an
(anti-PD-1) in melanoma. N Engl J Med 369:134, 2013. inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive
203. Bonini C, Ferrari G, Verzeletti S, et al: HSV-TK gene transfer into donor lymphocytes immunotherapy for lymphoma. PLoS One 8:e82742, 2013.
for control of allogeneic graft-versus-leukemia. Science 276:1719, 1997. 208. Di Stasi A, Tey S-K, Dotti G, et al: Inducible apoptosis as a safety switch for adoptive cell
204. Riddell SR, Elliott M, Lewinsohn DA, et al: T-cell mediated rejection of gene-modified therapy. N Engl J Med 365:1673, 2011.
HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med 2:216, 1996. 209. Zhou X, Di Stasi A, Tey SK, et al: Long-term outcome after haploidentical stem cell
205. Berger C, Blau CA, Huang ML, et al: Pharmacologically regulated Fas-mediated death transplant and infusion of T cells expressing the inducible caspase 9 safety transgene.
of adoptively transferred T cells in a nonhuman primate model. Blood 103:1261, 2004. Blood 123:3895, 2014.
206. Straathof KC, Pulè MA, Yotnda P, et al: An inducible caspase 9 safety switch for T-cell
therapy. Blood 105:4247, 2005.

Kaushansky_chapter 26_p0409-0420.indd 420 9/17/15 6:01 PM